Previously known as non-alcoholic fatty liver disease (NAFLD), MASLD is a hepatic condition characterized by excessive fat buildup in the liver due to metabolic factors, such as obesity, insulin resistance, hypertension, or high cholesterol levels. MASLD depicts how metabolic dysfunction can play an important role in liver fat accumulation. Furthermore, if left untreated, MASLD can progress leading to serious liver conditions, such as metabolic-associated steatohepatitis (MASH), fibrosis, cirrhosis, or even liver cancer. It is increasingly common worldwide and often occurs alongside type 2 diabetes and cardiovascular disease.
An upcoming hepatic research study at Lucida Clinical Trials aims to test how well multiple drugs work in treating adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) who are at high risk for serious liver problems, called Major Adverse Liver Outcomes (MALO).
